zhimin shao
Fudan U · Fudan University · Breast cancer institute of Fudan University Cancer Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
39
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in breast cancer
109
PubMed author-name match
Trials
Studies that name zhimin shao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:17 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07432178 · CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）Fudan University · recruiting · Breast Cancer · principal investigator
- Ph2NCT07419880 · Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast CancerFudan University · not yet recruiting · Triple -Negative Breast Cancer · principal investigator
- Ph3NCT07019363 · CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)Fudan University · recruiting · Breast Cancer, Adjuvant Therapy · principal investigator
- Ph3NCT06996093 · Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 InhibitorFudan University · not yet recruiting · Breast Cancer · principal investigator
- Ph3NCT06846437 · JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerShanghai JMT-Bio Inc. · recruiting · Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · principal investigator
- Ph2NCT06649331 · Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerFudan University · recruiting · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC) · principal investigator
- Ph3NCT06449027 · Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.Changchun GeneScience Pharmaceutical Co., Ltd. · active not recruiting · Breast Cancer Subjects · principal investigator
- Ph2NCT06404463 · QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerFudan University · not yet recruiting · Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer · principal investigator
- Ph3NCT06341621 · Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant AbemaciclibFudan University · recruiting · Breast Cancer · principal investigator
- Ph3NCT05954442 · Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeFudan University · unknown · Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation · principal investigator
- Ph2NCT05949541 · Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerFudan University · recruiting · Breast Cancer, Advanced Breast Cancer · principal investigator
- Ph4NCT05871437 · Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier GranulesFudan University · not yet recruiting · Breast Cancer · principal investigator
- Ph4NCT05860907 · Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisFudan University · not yet recruiting · Breast Cancer Stage IV · principal investigator
- Ph2NCT05749588 · FUSCC Refractory TNBC Platform Study (FUTURE2.0)Fudan University · recruiting · Triple-negative Breast Cancer · principal investigator
- Ph3NCT05673629 · Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast CancerBeijing Biostar Pharmaceuticals Co., Ltd. · unknown · Breast Cancer · principal investigator
- Ph2NCT05582499 · Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyFudan University · recruiting · Breast Neoplasm, Breast Cancer, Breast Tumors · principal investigator
- Ph2NCT05303038 · Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline TherapyFudan University · unknown · Metastatic Breast Cancer in the Liver · principal investigator
- Ph2NCT05076682 · Reverse Triple Negative Immune Resistant Breast CancerFudan University · recruiting · Triple-negative Breast Cancer · principal investigator
- Ph4NCT04790305 · Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerFudan University · recruiting · Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast · principal investigator
- Ph2NCT04734262 · A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Fudan University · active not recruiting · Metastatic Breast Cancer · principal investigator
- Ph3NCT04629846 · Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.Qilu Pharmaceutical Co., Ltd. · completed · Breast Cancer · principal investigator
- Ph3NCT04403529 · Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast CancerFudan University · unknown · Triple Negative Breast Cancer · principal investigator
- Ph3NCT04296175 · Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)Fudan University · active not recruiting · Triple-negative Breast Cancer · principal investigator
- Ph3NCT04193059 · Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerFudan University · active not recruiting · Breast Cancer · principal investigator
- Ph3NCT04174599 · Study to Compare the Efficacy and Safety of F-627 and GRAN®EVIVE Biotechnology · completed · Breast Cancer, Neutropenia · principal investigator
- Ph2NCT04129996 · A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Fudan University · unknown · Triple-Negative Breast Cancer · principal investigator
- Ph3NCT03980054 · A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerJiangsu HengRui Medicine Co., Ltd. · active not recruiting · Breast Cancer · study chair
- Ph3NCT03949634 · Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)Fudan University · unknown · Early Breast Cancer · principal investigator
- Ph3NCT03926091 · Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast CancerFudan University · unknown · Breast Cancer · principal investigator
- Ph4NCT03799679 · Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast CancerFudan University · unknown · Triple Negative Breast Cancer · principal investigator
- Ph4NCT03799692 · Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast CancerFudan University · unknown · HER-2 Negative Breast Cancer · principal investigator
- Ph3NCT03351062 · Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast CancerChinese Anti-Cancer Association · unknown · Breast Cancer Female · principal investigator
- Ph2NCT02628613 · Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 VariationsFudan University · completed · Breast Cancer · principal investigator
- Ph3NCT01642771 · Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast CancerChina Breast Cancer Clinical Study Group · unknown · Breast Cancer · principal investigator
- Ph2NCT01625429 · Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast CancerShanghai Cancer Hospital, China · unknown · Breast Cancer · principal investigator
- Ph2NCT01170143 · Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast CancerFudan University · unknown · Breast Cancer · principal investigator
- N/ANCT01116869 · China CellSearch StudyJohnson & Johnson Medical, China · completed · Metastatic Breast Cancer, Benign Breast Disease · principal investigator
- Ph3NCT01026116 · A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years OldFudan University · completed · Breast Neoplasms · principal investigator
- Ph3NCT00902954 · Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast CancerFudan University · unknown · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:17 UTC. The ranking covers the 200 most relevant of 109 PubMed records, and a shared surname and initials can bring in a namesake. All 109 on PubMed
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med · 20192,077 citationsRCR 85.1
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med · 20211,410 citationsRCR 78.5
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol · 2020882 citationsRCR 37.6
- 426 citationsRCR 12.8
- 399 citationsRCR 26.2
- 306 citationsRCR 16.2
- 242 citationsRCR 6.7
- 241 citationsRCR 11.6
- 232 citationsRCR 6.7
- Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol · 2020182 citationsRCR 7.0